3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Pain, Postoperative
2
Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spondylitis, Ankylosing
1
Sexual Dysfunction, Physiological
1
Pain
1
Ovarian Neoplasms
1
Mucositis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Chronic Pain
1
Anastomotic Leak
1
Agnosia
1
Acute Pain
1
Interventions
Cisplatin
136
Radiotherapy
90
Cetuximab
89
pembrolizumab
65
Fluorouracil
56
Docetaxel
56
Carboplatin
51
Paclitaxel
44
Radiotherapy, Intensity-Modulated
37
Nivolumab
35
durvalumab
19
Erlotinib Hydrochloride
18
Immunohistochemistry
16
Radiation
13
tremelimumab
12
Gemcitabine
11
Surgical Procedures, Operative
10
Gene Expression Profiling
10
Drug Therapy
10
Biopsy
10
Albumin-Bound Paclitaxel
10
Chemotherapy, Adjuvant
9
Capecitabine
9
Bevacizumab
9
atezolizumab
8
Radiosurgery
8
Polymerase Chain Reaction
8
Neoadjuvant Therapy
8
Ipilimumab
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Squamous Cell Carcinoma of Head and Neck
×
Anti-Inflammatory Agents, Non-Steroidal
×
Clear all
NCT02609386
2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2
Completed
105 enrolled
17 charts